Literature DB >> 19383788

ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells.

Maria Dafne Cardamone1, Chiara Bardella, Arantxa Gutierrez, Luciano Di Croce, Michael G Rosenfeld, Maria Flavia Di Renzo, Michele De Bortoli.   

Abstract

Estrogen receptor alpha (ERalpha) and E-cadherin are primary markers of luminal epithelial breast cancer cells with E-cadherin being a main caretaker of the epithelial phenotype. E-cadherin repression is needed for cancer cells to acquire motile and invasive properties, and it is known that in ER-positive breast cancer cells, estrogen down-regulate E-cadherin gene transcription. We report here that ERalpha is bound to the E-cadherin promoter in both the presence and the complete absence of estrogen, suggesting an unexpected role for unliganded ERalpha in E-cadherin transcription. Indeed, our data reveal that activation by unliganded ERalpha and repression by estrogen-activated ERalpha require direct binding to a half-estrogen response element within the E-cadherin promoter and exchange from associated coactivators to corepressors. Therefore, these results suggest a pivotal role for unliganded ERalpha in controlling a fundamental caretaker of the epithelial phenotype in breast cancer cells. Here, we show that ERalpha-positive breast cancer T47D cells transduced with the sfRON kinase undergo a full epithelial-mesenchymal conversion and lose E-cadherin and ERalpha expression. Our data show that, although the E-cadherin gene becomes hypermethylated and heterochromatic, kinase inhibitors can restore E-cadherin expression, together with an epithelial morphology in an ERalpha-dependent fashion. Similarly, transfection of ERalpha, in the absence of ligands, was sufficient to restore E-cadherin transcription in both sfRON-T47D and other ERalpha-, E-cadherin-negative cells. Therefore, our results suggest a novel role for the ERalpha that plays the dual role of ligand-independent activator and ligand-dependent repressor of E-cadherin in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383788      PMCID: PMC2671327          DOI: 10.1073/pnas.0903033106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia.

Authors:  P G Corn; B D Smith; E S Ruckdeschel; D Douglas; S B Baylin; J G Herman
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

2.  MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.

Authors:  Naoyuki Fujita; David L Jaye; Masahiro Kajita; Cissy Geigerman; Carlos S Moreno; Paul A Wade
Journal:  Cell       Date:  2003-04-18       Impact factor: 41.582

3.  Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.

Authors:  Martin Dutertre; Carolyn L Smith
Journal:  Mol Endocrinol       Date:  2003-04-24

4.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study.

Authors:  Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

5.  Estrogen-mediated down-regulation of E-cadherin in breast cancer cells.

Authors:  Steffi Oesterreich; Wanleng Deng; Shiming Jiang; Xiaojiang Cui; Margarita Ivanova; Rachel Schiff; Kaiyan Kang; Darryl L Hadsell; Jürgen Behrens; Adrian V Lee
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

6.  E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours.

Authors:  C L Chen; S S Liu; S M Ip; L C Wong; T Y Ng; H Y S Ngan
Journal:  Eur J Cancer       Date:  2003-03       Impact factor: 9.162

7.  K252a inhibits the oncogenic properties of Met, the HGF receptor.

Authors:  Alessandro Morotti; Silvia Mila; Paolo Accornero; Emma Tagliabue; Carola Ponzetto
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

Review 8.  Biological roles and mechanistic actions of co-repressor complexes.

Authors:  Kristen Jepsen; Michael G Rosenfeld
Journal:  J Cell Sci       Date:  2002-02-15       Impact factor: 5.285

9.  In vivo imaging of transcriptionally active estrogen receptors.

Authors:  Paolo Ciana; Michele Raviscioni; Paola Mussi; Elisabetta Vegeto; Ivo Que; Malcolm G Parker; Clemens Lowik; Adriana Maggi
Journal:  Nat Med       Date:  2002-12-16       Impact factor: 53.440

10.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Authors:  Pratyaksha Wirapati; Christos Sotiriou; Susanne Kunkel; Pierre Farmer; Sylvain Pradervand; Benjamin Haibe-Kains; Christine Desmedt; Michail Ignatiadis; Thierry Sengstag; Frédéric Schütz; Darlene R Goldstein; Martine Piccart; Mauro Delorenzi
Journal:  Breast Cancer Res       Date:  2008-07-28       Impact factor: 6.466

View more
  23 in total

1.  14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation.

Authors:  Zhaoyuan Hou; Hongzhuang Peng; David E White; Pu Wang; Paul M Lieberman; Thanos Halazonetis; Frank J Rauscher
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Genome-wide activity of unliganded estrogen receptor-α in breast cancer cells.

Authors:  Livia Caizzi; Giulio Ferrero; Santina Cutrupi; Francesca Cordero; Cecilia Ballaré; Valentina Miano; Stefania Reineri; Laura Ricci; Olivier Friard; Alessandro Testori; Davide Corà; Michele Caselle; Luciano Di Croce; Michele De Bortoli
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

3.  Differential recruitment of co-regulatory proteins to the human estrogen receptor 1 in response to xenoestrogens.

Authors:  L Cody Smith; Jessica C Clark; Joseph H Bisesi; P Lee Ferguson; Tara Sabo-Attwood
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2016-04-20       Impact factor: 2.674

4.  Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Authors:  Xuemei Liu; Ling Zhao; Yoko S Derose; Yi-Chun Lin; Magdalena Bieniasz; Henok Eyob; Saundra S Buys; Leigh Neumayer; Alana L Welm
Journal:  Genes Cancer       Date:  2011-07

5.  Epigenetic regulation of Kiss1 gene expression mediating estrogen-positive feedback action in the mouse brain.

Authors:  Junko Tomikawa; Yoshihisa Uenoyama; Makiko Ozawa; Tatsuya Fukanuma; Kenji Takase; Teppei Goto; Hitomi Abe; Nahoko Ieda; Shiori Minabe; Chikaya Deura; Naoko Inoue; Makoto Sanbo; Koichi Tomita; Masumi Hirabayashi; Satoshi Tanaka; Takuya Imamura; Hiroaki Okamura; Kei-ichiro Maeda; Hiroko Tsukamura
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-13       Impact factor: 11.205

6.  Genomic-Epidemiologic Evidence That Estrogens Promote Breast Cancer Development.

Authors:  Fritz F Parl; Philip S Crooke; W Dale Plummer; William D Dupont
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

7.  Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b.

Authors:  Natalie Goldberger; Renard C Walker; Chang Hee Kim; Scott Winter; Kent W Hunter
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

8.  Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.

Authors:  Xihong Zhang; Michael R Diaz; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2013-05-18       Impact factor: 4.872

9.  Unliganded estrogen receptor alpha promotes PC12 survival during serum starvation.

Authors:  François Ferriere; Denis Habauzit; Farzad Pakdel; Christian Saligaut; Gilles Flouriot
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Disseminated breast cancer cells acquire a highly malignant and aggressive metastatic phenotype during metastatic latency in the bone.

Authors:  Carolyn G Marsden; Mary Jo Wright; Latonya Carrier; Krzysztof Moroz; Brian G Rowan
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.